CliffBio
small molecule

IFEX

IFOSFAMIDE

Loss of exclusivity—loss of exclusivity
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameIFEX
Active ingredientIFOSFAMIDE
Strength3GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalDecember 1988
Marketing statusRX

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.